Abivax to Participate in Upcoming Fall Investor Conferences
Abivax will present at five fall investor conferences, Nov 9 to Dec 3, 2026, with no new clinical or financial data.
What this release says
Abivax says it will take part in several fall investor conferences between November 9 and December 3, 2026, including fireside chats and a corporate presentation. For a shareholder this is routine investor outreach and does not by itself disclose new results or financial terms.
Key figures
- Guggenheim conference fireside chat
- November 10, 2026, 10:30-10:55am ET
- German Equity Forum corporate presentation
- November 23, 2026, 11:40am-12:10pm CET
- Evercore ISI fireside chat
- December 2, 2026, 7:55-8:15am ET
- Piper Sandler fireside chat
- December 3, 2026, 8:00-8:25am ET
Positive for shareholders
- Webcasts for select presentations will be posted in the Investors section of the company website.
- Replays of available webcasts will be kept on the website for a limited time after each conference.
Written by Quantisnow AI from this release. Not financial advice.
Key terms
- Fireside chat:
- A informal, moderated conversation between a company executive and an investment analyst or host, held in front of an investor audience.
- Clinical-stage:
- Describes a company whose main products are still being tested in human trials and are not yet approved for sale.
FAQ
Where can shareholders watch Abivax's presentations at these conferences?
Webcast links for select presentations will be available in the Investors section of Abivax's website at www.ir.abivax.com, with replays available for a limited time.
What is Abivax's lead drug candidate mentioned in the release?
The release names obefazimod (ABX464), which is in Phase 3 clinical trials for moderately to severely active ulcerative colitis.
Historical context for ABVX
Across the 23 sessions after earlier ABVX headlines, the stock closed higher 10 times and lower 13 times, with a median move of 3.6% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | ABVX | SPY |
|---|---|---|---|
| Oct 1, 2026 | Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026 | -4.0% | +0.2% |
| Sep 22, 2026 | Abivax Presents Business Updates and First Half 2026 Financial Results | -5.0% | -0.0% |
| Jul 31, 2026 | Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod | +0.5% | +0.7% |
| Jul 24, 2026 | Abivax Strengthens Commercial Capabilities With Strategic Leadership Appointments | -4.2% | +0.1% |
| Jul 7, 2026 | Abivax Announces Closing of $920 Million Public Offering | -1.3% | -0.5% |
| Jul 2, 2026 | Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M) | +9.1% | -0.1% |
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2023
Follow ABVX and get a push notification the moment its next story breaks.